Knight Announces Closing of US$100 Million Revolving Credit Facility

Core Viewpoint - Knight Therapeutics Inc. has successfully closed a syndication of its US$100 million secured revolving credit facility, enhancing its financial flexibility for growth and acquisitions [1][3][5]. Group 1: Credit Facility Details - The credit facility was increased from an initial US$50 million to US$100 million, with an additional accordion feature allowing for another US$100 million, subject to lender acceptance [2][3]. - The facility has an initial maturity date of June 17, 2028, with the option for annual extensions of one year [4]. - The credit can be drawn in either USD or CAD at rates based on SOFR or CORRA plus a margin of 1.25% to 2.75%, depending on the company's debt leverage [4]. Group 2: Strategic Implications - The credit facility is intended to support the company's growth strategy and may also be utilized for working capital and other corporate purposes [3][5]. - The partnership with a consortium of four banks, led by National Bank of Canada, strengthens the company's financial relationships and doubles its borrowing capacity [5]. Group 3: Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [7].